Skip to main content
SpringerLink
Log in

Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene

  • Chapter
  • First Online:
Chemotherapy for Leukemia

Abstract

Retinoids, all-trans retinoic acid (ATRA), and tamibarotene can induce differentiation of leukemic cells that carry t(15;17) and potentially lead to complete remission (CR) in patients with acute promyelocytic leukemia (APL). Although introduction of ATRA as a differentiating agent has been a major breakthrough in the treatment of APL, ATRA is currently recognized as a molecular-targeted therapy directed at the PML-RARα chimeric protein, which is generated by the specific chromosomal translocation t(15;17). In several multicenter trials, more than 90% of newly diagnosed APL patients treated with ATRA and chemotherapy achieved CR, of whom 20–30% subsequently relapsed, and then approximately 80% of patients had overall survival. However, several problems still account for treatment failure including early death, death during consolidation, and disease relapse. Tamibarotene demonstrated efficacy in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.

    Article  CAS  PubMed  Google Scholar 

  2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol. 1980;44:169–70.

    Article  CAS  PubMed  Google Scholar 

  3. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79:543–53.

    CAS  PubMed  Google Scholar 

  4. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol. 2012;156:24–36. doi:10.1111/j.1365-2141.2011.08922.x.

    Article  CAS  PubMed  Google Scholar 

  5. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549–50.

    Article  CAS  PubMed  Google Scholar 

  6. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002;16:1959–73.

    Article  CAS  PubMed  Google Scholar 

  7. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 1990;249(4976):1577–80.

    Article  CAS  PubMed  Google Scholar 

  8. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347(6293):558–61.

    Article  PubMed  Google Scholar 

  9. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663–74.

    Article  CAS  PubMed  Google Scholar 

  10. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–72.

    CAS  PubMed  Google Scholar 

  11. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003;17:1454–63.

    Article  CAS  PubMed  Google Scholar 

  12. Asou N. All-trans retinoic acid in the treatment of acute promyelocytic leukemia. Intern Med. 2007;46:91–3.

    Article  PubMed  Google Scholar 

  13. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15. doi:10.1182/blood-2007-07-102798.

    Article  CAS  PubMed  Google Scholar 

  14. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–91. doi:10.1182/blood-2008-04-150250.

    Article  CAS  PubMed  Google Scholar 

  15. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29:495–503. doi:10.1200/JCO.2010.32.1067.

    Article  PubMed  Google Scholar 

  16. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391(6669):815–8.

    Article  CAS  PubMed  Google Scholar 

  17. Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391(6669):811–4.

    Article  CAS  PubMed  Google Scholar 

  18. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126–35.

    Article  CAS  PubMed  Google Scholar 

  19. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997;90:967–73.

    CAS  PubMed  Google Scholar 

  20. Takeuchi M, Yano T, Omoto E, Takahashi K, Kibata M, Shudo K, et al. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk Lymphoma. 1998;31:441–51.

    Article  CAS  PubMed  Google Scholar 

  21. Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol. 2014;32:3729–35. doi:10.1200/JCO.2013.53.3570.

    Article  CAS  PubMed  Google Scholar 

  22. Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, et al. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015;171:471–7. doi:10.1111/bjh.13607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395–402. doi:10.1182/blood-2007-07-100669.

    Article  PubMed  CAS  Google Scholar 

  24. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16:78–85.

    Article  CAS  PubMed  Google Scholar 

  25. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantù-Rajnoldi A, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998;102:1035–41.

    Article  CAS  PubMed  Google Scholar 

  26. Foley R, Soamboonsrup P, Carter RF, Benger A, Meyer R, Walker I, et al. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol. 2001;67:34–41.

    Article  CAS  PubMed  Google Scholar 

  27. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, et al. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010;116:5650–9. doi:10.1182/blood-2010-06-288613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447–52.

    Article  CAS  PubMed  Google Scholar 

  29. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153–60.

    Article  CAS  PubMed  Google Scholar 

  30. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167–215.

    CAS  PubMed  Google Scholar 

  31. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 2003;17:71–97.

    Article  PubMed  Google Scholar 

  32. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10:775–83. doi:10.1038/nrc2943.

    Article  PubMed  CAS  Google Scholar 

  33. de Thé H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol. 2012;198:11–21. doi:10.1083/jcb.201112044.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Nasr R, de Thé H. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol. 2010;91:742–7. doi:10.1007/s12185-010-0582-0.

    Article  PubMed  Google Scholar 

  35. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood. 2000;96:1297–308.

    CAS  PubMed  Google Scholar 

  36. Redner RL. Variations on a theme: the alternate translocations in APL. Leukemia. 2002;16:1927–32.

    Article  CAS  PubMed  Google Scholar 

  37. Adams J, Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med. 2015;139(10):1308–13. doi:10.5858/arpa.2013-0345-RS.

    Article  PubMed  Google Scholar 

  38. Iwanaga E, Nakamura M, Nanri T, Kawakita T, Horikawa K, Mitsuya H, et al. Acute promyelocytic leukemia harboring a STAT5B-RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B-RARA. Eur J Haematol. 2009;83:499–501. doi:10.1111/j.1600-0609.2009.01324.x.

    Article  CAS  PubMed  Google Scholar 

  39. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264–78. doi:10.1016/j.cell.2012.06.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016; doi:10.1038/leu.2016.69.

    Google Scholar 

  41. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94:2551–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A. 1997;94:5302–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood. 1997;89(2):376–87.

    CAS  PubMed  Google Scholar 

  44. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003;102:1857–65.

    Article  CAS  PubMed  Google Scholar 

  45. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia. 2002;16:1896–905.

    Article  CAS  PubMed  Google Scholar 

  46. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377(6548):454–7.

    Article  CAS  PubMed  Google Scholar 

  47. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995;377(6548):397–404.

    Article  PubMed  Google Scholar 

  48. Chih DY, Chumakov AM, Park DJ, Silla AG, Koeffler HP. Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBP epsilon). Blood. 1997;90:2987–94.

    CAS  PubMed  Google Scholar 

  49. Daniel MT, Koken M, Romagné O, Barbey S, Bazarbachi A, Stadler M, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood. 1993;82:1858–67.

    CAS  PubMed  Google Scholar 

  50. Dyck JA, Maul GG, Miller Jr WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 1994;76:333–43.

    Article  CAS  PubMed  Google Scholar 

  51. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 1994;13:1073–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Ferbeyre G. PML a target of translocations in APL is a regulator of cellular senescence. Leukemia. 2002;16:1918–26.

    Article  CAS  PubMed  Google Scholar 

  53. Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol. 2002;22:5259–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453(7198):1072–8. doi:10.1038/nature07016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 1993;12:3171–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A. 1999;96:14807–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 2005;7:143–53.

    Article  CAS  PubMed  Google Scholar 

  58. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94:3978–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328(5975):240–3. doi:10.1126/science.1183424.

    Article  CAS  PubMed  Google Scholar 

  60. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008;14:1333–42. doi:10.1038/nm.1891.

    Article  CAS  PubMed  Google Scholar 

  61. Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385–93.

    Article  PubMed  Google Scholar 

  62. Ohno R, Ohnishi K, Takeshita A, Tanimoto M, Murakami H, Kanamaru A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia. 1994;8(Suppl 3):S64–9.

    PubMed  Google Scholar 

  63. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995;85:1202–6.

    CAS  PubMed  Google Scholar 

  64. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell Jr RP. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992;117:292–6.

    Article  CAS  PubMed  Google Scholar 

  65. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021–8.

    Article  CAS  PubMed  Google Scholar 

  66. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82:3241.

    CAS  PubMed  Google Scholar 

  67. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94:1192–200.

    CAS  PubMed  Google Scholar 

  68. Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115:1690–6. doi:10.1182/blood-2009-07-233387.

    Article  PubMed  CAS  Google Scholar 

  69. Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006;24:5703–10.

    Article  PubMed  CAS  Google Scholar 

  70. Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol. 2013;88:556–9. doi:10.1002/ajh.23451.

    Article  PubMed  CAS  Google Scholar 

  71. Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117:4716–25. doi:10.1182/blood-2010-08-302950.

    Article  CAS  PubMed  Google Scholar 

  72. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116:3171–9. doi:10.1182/blood-2010-03-276196.

    Article  CAS  PubMed  Google Scholar 

  73. Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94:3015–21.

    CAS  PubMed  Google Scholar 

  74. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237–43.

    Article  CAS  PubMed  Google Scholar 

  75. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298–302.

    Article  CAS  PubMed  Google Scholar 

  76. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751–7. doi:10.1182/blood-2010-02-269621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110:59–66.

    Article  CAS  PubMed  Google Scholar 

  78. Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, et al. Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci. 2012;103:1974–8. doi:10.1111/j.1349-7006.2012.02390.x.

    Article  CAS  PubMed  Google Scholar 

  79. Sanz MA, Labopin M, Gorin NC, de la Rubia J, Arcese W, Meloni G, et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2007;39:461–9.

    Article  CAS  PubMed  Google Scholar 

  80. Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, et al. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. Cancer Sci. 2013;104:1339–45. doi:10.1111/cas.12230.

    Article  CAS  PubMed  Google Scholar 

  81. Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–53.

    CAS  PubMed  Google Scholar 

  82. Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111:1078–84.

    Article  PubMed  Google Scholar 

  83. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128–34. doi:10.1038/leu.2011.78.

    Article  CAS  PubMed  Google Scholar 

  84. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21. doi:10.1056/NEJMoa1300874.

    Article  CAS  PubMed  Google Scholar 

  85. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295–305. doi:10.1016/S1470-2045(15)00193-X.

    Article  CAS  PubMed  Google Scholar 

  86. Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213–9.

    Article  PubMed  Google Scholar 

  87. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92:2712–8.

    CAS  PubMed  Google Scholar 

  88. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95:90–5.

    Google Scholar 

  89. Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113:775–83. doi:10.1182/blood-2008-07-168617.

    Article  CAS  PubMed  Google Scholar 

  90. Asou N. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia. Intern Med. 2005;44:775–6.

    Article  PubMed  Google Scholar 

  91. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120:1570–80.

    Article  CAS  PubMed  Google Scholar 

  92. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell’Adulto. J Clin Oncol. 2001;19:4023–8.

    Article  CAS  PubMed  Google Scholar 

  93. de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006;20:35–41.

    Article  PubMed  CAS  Google Scholar 

  94. Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, et al. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials). Leukemia. 2006;20:905–7.

    Article  CAS  PubMed  Google Scholar 

  95. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol. 1999;17:293–7.

    Article  CAS  PubMed  Google Scholar 

  96. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295–300.

    Article  CAS  PubMed  Google Scholar 

  97. Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6):1799–805. doi:10.1182/blood-2010-04-277434.

    Article  CAS  PubMed  Google Scholar 

  98. Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, et al. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci. 2014;105:97–104. doi:10.1111/cas.12319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Miller Jr WH, Kakizuka A, Frankel SR, Warrell Jr RP, DeBlasio A, Levine K, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1992;89:2694–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94:2225.

    CAS  PubMed  Google Scholar 

  101. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995–9.

    Article  CAS  PubMed  Google Scholar 

  102. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650–8. doi:10.1200/JCO.2008.20.1533.

    Article  CAS  PubMed  Google Scholar 

  103. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002;16:1940–58.

    Article  CAS  PubMed  Google Scholar 

  104. Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol. 2013;97:717–25. doi:10.1007/s12185-013-1354-4.

    Article  CAS  PubMed  Google Scholar 

  105. Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, et al. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica. 1999;84:963–8.

    CAS  PubMed  Google Scholar 

  106. Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, et al. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012;120:2098–108. doi:10.1182/blood-2012-01-407601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol. 2005;23:120–6.

    Article  PubMed  CAS  Google Scholar 

  108. Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013;121:3095–102. doi:10.1182/blood-2012-11-466862.

    Article  CAS  PubMed  Google Scholar 

  109. Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol. 2001;115:63–5.

    Article  CAS  PubMed  Google Scholar 

  110. Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, et al. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17:1085–90.

    Article  CAS  PubMed  Google Scholar 

  111. Sanz MA, Vellenga E, Rayón C, Díaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104:3490–3.

    Article  CAS  PubMed  Google Scholar 

  112. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19:230–3.

    Article  CAS  PubMed  Google Scholar 

  113. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99:822–4.

    Article  CAS  PubMed  Google Scholar 

  114. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003;17:1600–4.

    Article  CAS  PubMed  Google Scholar 

  115. Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol. 2010;28:3872–9. doi:10.1200/JCO.2010.29.2268.

    Article  CAS  PubMed  Google Scholar 

  116. Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009;94:54–60. doi:10.3324/haematol.13378.

    Article  CAS  PubMed  Google Scholar 

  117. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 2010;115:948–56. doi:10.1182/blood-2009-08-236588.

    Article  CAS  PubMed  Google Scholar 

  118. El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood. 2015;125:3447–54. doi:10.1182/blood-2014-11-612416.

    Article  CAS  PubMed  Google Scholar 

  119. Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125:3455–65. doi:10.1182/blood-2014-11-611459.

    Article  CAS  PubMed  Google Scholar 

  120. Verhagen HJ, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, et al. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood. 2016;127:458–63. doi:10.1182/blood-2015-07-653840.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The author declares no potential conflicts of interest. This work was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sport, Science, and Technology (JSPS KAKENHI Grant number 26461431); by the National Cancer Center Research and Development Fund (26-A-24); by Grants-in-Aid from the Cancer Research from the Japanese Ministry of Health, Labor and Welfare (Clinical Cancer Research 23-004); by the MHLW KAKENHI Grant Number H26-Kakushintekigan-Ippan-133; by Grants-in-Aid from the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct); and by the Japan Leukaemia Research Fund.

Author information

Authors and Affiliations

  1. Department of Hematology, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan

    Norio Asou

Authors
  1. Norio Asou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norio Asou .

Editor information

Editors and Affiliations

  1. University of Fukui, Fukui, Japan

    Takanori Ueda

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Asou, N. (2017). Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene. In: Ueda, T. (eds) Chemotherapy for Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-10-3332-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-3332-2_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-3330-8

  • Online ISBN: 978-981-10-3332-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation